Please fill out the form below and we will get back to you as soon as possible.
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.
New uses of pharmaceutical or biotechnological compounds or compositions have been protected through patents for a long time in Mexico as far as all patentability requirements were meet.
Acceptance of patentability of new uses are in line with the commitments acquired by Mexico with the World Trade Organization (WTO) by means of the TRIPS Agreement which requires countries to make patents available for any inventions, whether products or processes, in all fields of technology without discrimination.
Nevertheless, the current Mexican IP Law only provides that variations of use are not considered as inventions except that the use is not obvious for a person with an ordinary skill in the art and thus, it has been sought for many years that the law provides a clearer support for use patents.
The new Federal Law for Protection of the Industrial Property that will come into force on November 5, 2020 expressly provides that patentability of substances, compounds or compositions contained in the state of the art cannot be excluded from the patentability as along as the use thereof is new.
This express provision in the new Mexican IP Law fills some gaps present in the current Mexican Law, which will be positive for the Mexican IP system, as it provides certainty to the pharmaceutical sector. Furthermore, the recognition of the patentability of said type of inventions complies with the agreement reached between the United States – Mexico – Canada Agreement (USMCA) which also includes provisions to make patents available for inventions in all fields of technology.
As informed in our previous newsletters, Regulations of the new Mexican IP Law are still pending so that we will be attentive to the implementation process. It is expected that said Regulations include the revision of claim drafting accepted to claim first, second and further medical uses, since based on the current practice, purpose limited product and Swiss type formats are accepted to claim new uses though they are not included in the current Mexican IP Law or Regulations.
Partner
Partner
Partner
